Company
(symbol)#*

Date filed

Shares/units (M)

Price

Shares out@

Lead, other underwriters

Gross (US$M)

INITIAL OFFERINGS

Advanced Accelerator Applications SA (Saint Genis Pouilly, France; AAAP)

11/17/14

ADS

N/A

N/A

Citigroup (co-lead); Jefferies (co-lead); Canaccord Genuity; JMP Securities

$100

Altheadx Inc. (San Diego; IDGX)

12/23/14

N/A

N/A

17.9

Citigroup (co-lead); Jefferies (co-lead); William Blair; Cantor Fitzgerald & Co.

$69

Bone Therapeutics SA (Gosselies, Belgium; NYSE Euronext)

1/20/15

N/A

N/A

N/A

N/A

$29

Cantargia AB (Lund, Sweden; OMX)1

1/30/15

5.8S

SEK7.6

N/A

N/A

$5.4

Carbylan Therapeutics Inc. (Palo Alto, Calif.; CBYL)2

12/29/14

5.8S

$12-$14

N/A

Leerink Partners (lead); JMP Securities; Wedbush Pacgrow Life Sciences

$75.4

Cellectis SA (Paris; NYSE Alternext:ALCLS)

1/9/15

N/A

N/A

N/A

N/A

N/A

Clarus Therapeutics Inc. (Northbrook, Ill.; CLRS)

5/23/14

N/A

N/A

N/A

Citigroup (co-lead); Credit Suisse (co-lead); Canaccord Genuity; Needham & Co.

$86.25

Eyegate Pharma Inc. (Waltham, Mass.; EYEG)3

7/31/14

1.43S

$6-$8

6.94

Aegis Capital (co-lead); Chardan Capital Markets (co-lead)

$10

Inotek Pharmaceuticals Corp. (Lexington, Mass.; ITEK)

11/5/14

4.643S

$13-$15

N/A

Cowen and Co. (co-lead); Piper Jaffray (co-lead); Canaccord Genuity; Nomura

$65

Lumena Pharmaceuticals Inc. (San Diego; LIVR)

4/2/14

N/A

N/A

N/A

Citigroup (co-lead); Cowen and Co. (co-lead); Leerink Partners (co-lead)

$75

Oncore Biopharma Inc. (Doylestown, Pa.)4

11/25/14

N/A

N/A

N/A

N/A

N/A

Redx Pharmaceuticals Ltd. (Liverpool, UK; London's AIM)

1/20/15

N/A

N/A

N/A

N/A

$30.3

Revo Biologics Inc. (Framingham, Mass.; RBIO)5

6/25/14

3.6S

$13-$15

18.4

Piper Jaffray (co-lead); Guggenheim Securities (co-lead); Roth Capital Partners; BTIG

$50.4

S1 Biopharma Inc. (New York; SXB)6

10/1/14

1.75S

$12-$14

8.13

MLV & Co. (lead); Northland Securities

$22.75

Silenseed Ltd. (Jerusalem; RNAI)

6/18/14

N/A

N/A

N/A

Aegis Capital Corp. (lead)

$36.4

Summit Corp. (Oxford, UK)7

2/3/15

N/A

N/A

N/A

N/A

$40

Tobira Therapeutics Inc. (South San Francisco; TBRA)

10/20/14

N/A

N/A

N/A

Leerink Partners (co-lead); Oppenheimer & Co. (co-lead); Needham & Co. (co-lead)

$69

Tracon Pharmaceuticals Inc. (San Diego; TCON)

12/29/14

3.6S

$12-$14

11.98

Wells Fargo Securities (co-lead); Stifel (co-lead); Needham & Co.; Oppenheimer & Co.

$46.8

Viking Therapeutics Inc. (San Diego; VKTX)8

7/1/14

5S

$10-$12

15.15

Oppenheimer & Co. (co-lead); Roth Capital Partners (co-lead); MLV & Co.; Craig-Hallum Capital Group; Summer Street Research Partners

$55

Notes

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

* Stock symbols for companies seeking to complete IPOs are proposed.

@ This column reflects the shares outstanding following the offering, when disclosed.

N/A = Not available, applicable or reported.

The value of all offerings is based on either the midpoint of the price range listed in the company's SEC filing or the maximum aggregate offering price listed in the SEC filing.

This chart includes only biotech companies that develop therapeutics.

1 Cantargia aims to raise SEK44.1M (US$5.4M) in an IPO on the Nasdaq OMX First North exchange.

2 Carbylan's overallotment option: 870,000 shares.

3 Eyegate's overallotment option: 214,286 shares.

4 Oncore Biopharma confidentially submitted a draft registration statement to the SEC for a proposed IPO.

5 Revo's overallotment option: 540,000 shares.

6 S1's overallotment option: 262,500 shares.

7 Summit filed an F-1 seeking to raise $40M in an IPO.

8 Viking's overallotment option: 750,000 shares.